Leveraging collaborations and internal discoveries, we have built a robust pipeline with strong potentials, including 11 drug candidates in development. Currently, four of them are being investigated in clinical trials, which are Buparlisib (AN2025), Pelareorep (AN1004), an oral EP4 antagonist (AN0025) and oral small-molecule PD-L1 inhibitor (AN4005).